CEO Gilmore O'Neill was paid $2,353,655 in fiscal year 2025, ↓ down 54.1% from fiscal year 2024, the 31st percentile of its disclosed peer group (SEC filing 0001650664-26-000037 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$2,353,655 ↓ Gilmore O'Neill total, FY2025 | 31st CEO pay percentile vs peers | — CEO-to-median pay ratio | 83.89% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
EDIT's next annual pay disclosure, estimated May 11, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Gilmore O'Neill | $686,574 | $0 | $0 | $1,282,937 | $375,164 | $0 | $8,980 | $2,353,655 |
| President and Chief Executive Officer | ||||||||
| Linda Burkly | 517,169 | 0 | 0 | 441,417 | 206,993 | 0 | 10,810 | 1,176,389 |
| Executive Vice President and Chief Scientific Officer | ||||||||
| Amy Parison | 394,202 | 0 | 0 | 266,135 | 154,048 | 0 | 7,270 | 821,655 |
| Senior Vice President and Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Gilmore O'Neill | $2,353,655 | $5,126,868 | $2,392,309 | ↓ −2,773,213 |
| Linda Burkly | 1,176,389 | — | 1,537,048 | — |
| Amy Parison | 821,655 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Editas Medicine's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper EDIT reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
Each company listed discloses EDIT in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named EDIT in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Andrew Hirsch | Independent Director | $118,713 |
| Bernadette Connaughton | Independent Director | $112,463 |
| David T. Scadden, M.D | Independent Director | $99,963 |
| Elliott Levy, M.D | Independent Director | $101,213 |
| Gilmore O'Neill, M.B., M.M.Sc | Director | — |
| Jessica Hopfield, Ph.D | Chair of the Board | $146,213 |
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Gilmore O'Neill | Director | 2026-06-03 | D | 15,380 | $3 | $41,543 | Common | Form 4 ↗ |
| Amy Parison | SVP, Chief Financial Officer | 2026-06-03 | D | 464 | 3 | 1,253 | Common | Form 4 ↗ |
| Linda Burkly | EVP, CHIEF SCIENTIFIC OFFICER | 2026-06-03 | D | 731 | 3 | 1,975 | Common | Form 4 ↗ |
| Bernadette Connaughton | Director | 2026-06-17 | A | 51,700 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Hirsch | Director | 2026-06-17 | A | 51,700 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Elliott M. Levy | Director | 2026-06-17 | A | 51,700 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Scadden | Director | 2026-06-17 | A | 51,700 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jessica Hopfield | Director | 2026-06-17 | A | 51,700 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Linda Burkly | EVP, CHIEF SCIENTIFIC OFFICER | 2026-07-28 | D | 4,928 | 3 | 13,158 | Common | Form 4 ↗ |
| Amy Parison | SVP, Chief Financial Officer | 2026-08-03 | D | 678 | 3 | 1,749 | Common | Form 4 ↗ |
| Patrick Thomas Ellinor II | Director | 2026-08-06 | A | 103,400 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gilmore O'Neill | Director | 2026-09-03 | D | 5,124 | 3 | 15,563 | Common | Form 4 ↗ |
| Amy Parison | SVP, Chief Financial Officer | 2026-09-03 | D | 453 | 3 | 1,376 | Common | Form 4 ↗ |
| Linda Burkly | EVP, CHIEF SCIENTIFIC OFFICER | 2026-09-03 | D | 709 | 3 | 2,153 | Common | Form 4 ↗ |
| Daniel Scott Ory | EVP, Chief Medical Officer | 2026-09-08 | A | 950,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Amy Parison | OPTION | — | — | — | — | — | $266,135 |
| Gilmore O'Neill | OPTION | — | — | — | — | — | 1,282,937 |
| Linda Burkly | OPTION | — | — | — | — | — | 441,417 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Amy Parison | $0 | $0 | $266,135 | 0.0% |
| Gilmore O'Neill | 0 | 0 | 1,282,937 | 0.0% |
| Linda Burkly | 0 | 0 | 441,417 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Linda Burkly | RSU | 30,112 | — | $61,730 |
| Amy Parison | Option | 1,903 | 8.72 | — |
| Gilmore O'Neill | Option | 672,750 | 1.72 | — |
| Linda Burkly | Option | 53,635 | 8.66 | — |
| Gilmore O'Neill | RSU | 73,519 | — | 150,714 |
| Amy Parison | Option | 118,258 | 1.72 | — |
| Amy Parison | Option | 4,475 | 15.83 | — |
| Linda Burkly | RSU | 22,583 | — | 46,295 |
| Linda Burkly | RSU | 13,950 | — | 28,598 |
| Amy Parison | RSU | 6,457 | — | 13,237 |
| Linda Burkly | Option | 41,850 | 9.92 | — |
| Amy Parison | RSU | 1,491 | — | 3,057 |
| Gilmore O'Neill | RSU | 15,625 | — | 32,031 |
| Linda Burkly | Option | 70,000 | 1.72 | — |
| Amy Parison | Option | 28,893 | 0.98 | — |
| Linda Burkly | Option | 223,519 | 1.72 | — |
| Amy Parison | Option | 42,880 | 1.72 | — |
| Amy Parison | Option | 9,686 | 9.92 | — |
| Gilmore O'Neill | RSU | 130,700 | — | 267,935 |
| Gilmore O'Neill | RSU | 85,000 | — | 174,250 |
| Linda Burkly | RSU | 49,600 | — | 101,680 |
| Gilmore O'Neill | RSU | 21,663 | — | 44,409 |
| Gilmore O'Neill | Option | 175,000 | 1.72 | — |
| Amy Parison | RSU | 1,228 | — | 2,599 |
| Gilmore O'Neill | Option | 220,556 | 9.92 | — |
| Gilmore O'Neill | Option | 118,776 | 11.54 | — |
| Gilmore O'Neill | Option | 46,875 | 8.72 | — |
Our compensation programs are designed to attract and retain qualified and talented executives, motivate such executives to achieve our business goals and reward them for short- and long-term performance.
| CEO STI target (% of salary) | 60% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pearl Meyer & Partners, LLC |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-17 | 32,914,258 | 6,322,885 | 212,587 | 83.89% | Passed |
| 2025 | 2025-05-29 | 16,066,738 | 10,241,052 | 221,690 | 61.07% | Passed |
| 2024 | 2024-05-30 | 38,609,828 | 2,769,887 | 205,788 | 93.31% | Passed |
| 2023 | 2023-06-01 | 27,178,082 | 3,102,043 | 215,685 | 89.76% | Passed |
| 2022 | 2022-06-09 | 27,094,152 | 4,523,649 | 332,696 | 85.69% | Passed |
| 2021 | 2021-06-03 | 31,762,876 | 2,875,374 | 207,961 | 91.7% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-06-17 | 83.89%a |
| 2025 | 2025-05-29 | 61.07%b |
| 2024 | 2024-05-30 | 93.31%c |
a. Approved under the standard stated in the filing — “Abstentions and broker non-votes will not be counted as votes cast or voted on any of the proposals.”.
b. Approved under the standard stated in the filing — “Abstentions and broker non-votes will not be counted as votes cast or voted on any of the proposals.”.
c. Approved under the standard stated in the filing — “Abstentions and broker non-votes will not be counted as votes cast or voted on any of the proposals.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Jessica Hopfield, Ph.DIndependent · Board Chair · Audit · Nominating/Governance (Chair) | $93,750 | $0 | $52,463 | $0 | $0 | $146,213 |
| Andrew HirschIndependent · Audit (Chair) · Compensation | 66,250 | 0 | 52,463 | 0 | 0 | 118,713 |
| Bernadette ConnaughtonIndependent · Compensation (Chair) · Nominating/Governance | 60,000 | 0 | 52,463 | 0 | 0 | 112,463 |
| Elliott Levy, M.DIndependent · Audit | 48,750 | 0 | 52,463 | 0 | 0 | 101,213 |
| David T. Scadden, M.DIndependent · Compensation | 47,500 | 0 | 52,463 | 0 | 0 | 99,963 |
| Gilmore O'Neill, M.B., M.M.ScEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | $300,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 18,750 / 15,000 / 10,000 |
| Stock ownership guideline | Set robust executive and non-employee director Stock Ownership Guidelines |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $316,250 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $316,250 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Editas Medicine names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Editas Medicine.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Solid Biosciences Inc. | 2025 | Alexander Cumbo | $650,988 | $2,318,275 | $1,792,397 | $0 | $5,223,442 |
| 2 | Lyell Immunopharma, Inc. | 2025 | Lynn Seely | 690,173 | 186,806 | 2,907,551 | 414,000 | 4,222,265 |
| 3 | Prime Medicine, Inc. | 2025 | Allan Reine | 606,212 | 0 | 2,828,798 | 402,000 | 3,894,187 |
| 4 | Lexeo Therapeutics, Inc. | 2025 | R. Nolan Townsend | 632,700 | 1,493,488 | 1,165,982 | 347,985 | 3,650,940 |
| 5 | Neurogene Inc. | 2025 | Rachel McMinn | 618,800 | 385,746 | 1,826,570 | 0 | 3,209,553 |
| 6 | Nkarta, Inc. | 2025 | Paul Hastings | 674,384 | 236,250 | 1,711,957 | 344,947 | 2,978,038 |
| 7 | TScan Therapeutics, Inc. | 2025 | Gavin MacBeath | 665,000 | 0 | 1,982,800 | 139,650 | 2,801,450 |
| 8 | Voyager, Inc. | 2025 | Alfred Sandrock | 674,903 | 611,900 | 843,900 | 361,917 | 2,508,370 |
| 9 | Cabaletta Bio, Inc. | 2025 | Steven Nichtberger | 659,550 | 0 | 1,266,978 | 446,982 | 2,401,555 |
| 10 | Editas Medicine | 2025 | Gilmore O'Neill | 686,574 | 0 | 1,282,937 | 375,164 | 2,353,655 |
| 11 | Fate Therapeutics, Inc. | 2025 | Bahram Valamehr | 600,000 | 0 | 1,283,868 | 360,000 | 2,248,568 |
| 12 | Tenaya Therapeutics, Inc. | 2025 | Faraz Ali | 664,173 | 141,924 | 755,507 | 319,275 | 1,881,396 |
| 13 | Caribou Biosciences, Inc. | 2025 | Rachel Haurwitz | 667,534 | 192,818 | 654,541 | 0 | 1,840,965 |
| 14 | Adicet Bio, Inc. | 2025 | Chen Schor | 646,294 | 0 | 512,079 | 284,592 | 1,465,747 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Editas Medicine | 91% | Options 100 | not disclosed | Pearl Meyer & Partners, LLC |
| Adicet Bio, Inc. | not disclosed | not disclosed | not disclosed | Aon Consulting, Inc. |
| Cabaletta Bio, Inc. | 114.49% | Options 100 | not disclosed | Aon |
| Caribou Biosciences, Inc. | not disclosed | not disclosed | not disclosed | Alpine Rewards, LLC |
| Fate Therapeutics, Inc. | 100% | Options 100 | No | Aon's Human Capital Solutions practice (Radford) |
| Lexeo Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Alpine Rewards, LLC |
| Lyell Immunopharma, Inc. | 100% | not disclosed | No | Alpine |
| Neurogene Inc. | not disclosed | not disclosed | not disclosed | Aon |
| Nkarta, Inc. | not disclosed | not disclosed | not disclosed | Aon Consulting, Inc. |
| Prime Medicine, Inc. | 120% | not disclosed | not disclosed | Alpine Rewards |
| Solid Biosciences Inc. | 100% | not disclosed | No | Radford (AON Hewitt) |
| Tenaya Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Pearl Meyer |
| TScan Therapeutics, Inc. | not disclosed | Options 100 | not disclosed | not disclosed |
| Voyager, Inc. | 97.5% | not disclosed | No | Alpine Rewards, LLC |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Gilmore O'Neill | DEF 14A | 2026-04-28 | 0001650664-26-000037 | Section “2025 Summary Compensation Table”. As printed: 2,353,655. Filing ↗machine: t42 · r2 · c12 · span 545455–545464 |
| 2 | Section 01, Linda Burkly | DEF 14A | 2026-04-28 | 0001650664-26-000037 | Section “2025 Summary Compensation Table”. As printed: 1,176,389. Filing ↗machine: r4 · c21 · span 550598–550607 |
| 3 | Section 01, Amy Parison | DEF 14A | 2026-04-28 | 0001650664-26-000037 | Section “2025 Summary Compensation Table”. As printed: 821,655. Filing ↗machine: r6 · c21 · span 553910–553917 |
| 4 | Section 03, Amy Parison OPTION | DEF 14A | 2026-04-28 | 0001650664-26-000037 | Section “TABLE OF CONTENTS EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t42 · r6 · c6 · span 552889–552896 |
| 5 | Section 03, Gilmore O'Neill OPTION | DEF 14A | 2026-04-28 | 0001650664-26-000037 | Section “TABLE OF CONTENTS EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t42 · r2 · c6 · span 544258–544267 |
| 6 | Section 03, Linda Burkly OPTION | DEF 14A | 2026-04-28 | 0001650664-26-000037 | Section “TABLE OF CONTENTS EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t42 · r4 · c6 · span 549576–549583 |
| 7 | Section 07, pay ratio | 10-K | 2026-03-09 | 0001650664-26-000017 | Section “CEO Pay Ratio”. As printed: —. Filing ↗ |
| 8 | Section 08, Jessica Hopfield, Ph.D | DEF 14A | 2026-04-28 | 0001650664-26-000037 | Section “Director Compensation”. As printed: 146,213. Filing ↗machine: t50 · r4 · c5 · span 785079–785321 |
| 9 | Section 08, Andrew Hirsch | DEF 14A | 2026-04-28 | 0001650664-26-000037 | Section “Director Compensation”. As printed: 118,713. Filing ↗machine: t50 · r3 · c5 · span 783783–784025 |
| 10 | Section 08, Bernadette Connaughton | DEF 14A | 2026-04-28 | 0001650664-26-000037 | Section “Director Compensation”. As printed: 112,463. Filing ↗machine: t50 · r2 · c5 · span 782439–782710 |
| 11 | Section 08, Elliott Levy, M.D | DEF 14A | 2026-04-28 | 0001650664-26-000037 | Section “Director Compensation”. As printed: 101,213. Filing ↗machine: t50 · r5 · c5 · span 786369–786611 |
| 12 | Section 08, David T. Scadden, M.D | DEF 14A | 2026-04-28 | 0001650664-26-000037 | Section “Director Compensation”. As printed: 99,963. Filing ↗machine: t50 · r6 · c5 · span 787664–787905 |
| 13 | Section 08, Gilmore O'Neill, M.B., M.M.Sc | DEF 14A | 2026-04-28 | 0001650664-26-000037 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 14 | Section 02, Gilmore O'Neill 2026-06-03 | Form 4 | 2026-06-05 | 0001650664-26-000056 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 15 | Section 02, Amy Parison 2026-06-03 | Form 4 | 2026-06-05 | 0001650664-26-000057 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 16 | Section 02, Linda Burkly 2026-06-03 | Form 4 | 2026-06-05 | 0001650664-26-000055 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 17 | Section 02, Bernadette Connaughton 2026-06-17 | Form 4 | 2026-06-22 | 0001650664-26-000072 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 18 | Section 02, Andrew Hirsch 2026-06-17 | Form 4 | 2026-06-22 | 0001650664-26-000070 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 19 | Section 02, Elliott M. Levy 2026-06-17 | Form 4 | 2026-06-22 | 0001650664-26-000068 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 20 | Section 02, David Scadden 2026-06-17 | Form 4 | 2026-06-22 | 0001650664-26-000069 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 21 | Section 02, Jessica Hopfield 2026-06-17 | Form 4 | 2026-06-22 | 0001650664-26-000071 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 22 | Section 02, Linda Burkly 2026-07-28 | Form 4 | 2026-07-29 | 0001650664-26-000076 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 23 | Section 02, Amy Parison 2026-08-03 | Form 4 | 2026-08-05 | 0002063082-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 24 | Section 02, Patrick Thomas Ellinor II 2026-08-06 | Form 4 | 2026-08-07 | 0002137699-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 25 | Section 02, Gilmore O'Neill 2026-09-03 | Form 4 | 2026-09-04 | 0001742084-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 26 | Section 02, Amy Parison 2026-09-03 | Form 4 | 2026-09-04 | 0002063082-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 27 | Section 02, Linda Burkly 2026-09-03 | Form 4 | 2026-09-04 | 0001985604-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 28 | Section 02, Daniel Scott Ory 2026-09-08 | Form 4 | 2026-09-09 | 0002149618-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 29 | Section 06, 2026 vote | Form 8-K | 2026-06-18 | 0001650664-26-000063 | Item 5.07 · say-on-pay result. As reported: 83.89% (votes for as printed: 32,914,258). Filing ↗ |
| 30 | Section 06, 2025 vote | Form 8-K | 2025-06-02 | 0001650664-25-000086 | Item 5.07 · say-on-pay result. As reported: 61.07% (votes for as printed: 16,066,738). Filing ↗ |
| 31 | Section 06, 2024 vote | Form 8-K | 2024-05-31 | 0001650664-24-000050 | Item 5.07 · say-on-pay result. As reported: 93.31% (votes for as printed: 38,609,828). Filing ↗ |
| 32 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 33 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 34 | Section 09b board cost (computed) | Computed | — | — | Cash 316,250 + equity 0 + all other 0 = 316,250, summed across the director compensation table rows.machine: formula: Σ = 316,250 |
| 35 | Solid Biosciences Inc., Section 10b CEO total | DEF 14A | 2026-04-23 | 0001193125-26-173642 | CEO total compensation as printed in Solid Biosciences Inc.'s own proxy. As printed: 5,223,442. Filing ↗machine: r2 · c25 · span 472915–472924 |
| 36 | Lyell Immunopharma, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001140361-26-016686 | CEO total compensation as printed in Lyell Immunopharma, Inc.'s own proxy. As printed: 4,222,265. Filing ↗machine: r2 · c24 · span 450163–450172 |
| 37 | Prime Medicine, Inc., Section 10b CEO total | DEF 14A | 2026-04-23 | 0001628280-26-026697 | CEO total compensation as printed in Prime Medicine, Inc.'s own proxy. As printed: 3,894,187. Filing ↗machine: r2 · c42 · span 285179–285188 |
| 38 | Lexeo Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-30 | 0001193125-26-193930 | CEO total compensation as printed in Lexeo Therapeutics, Inc.'s own proxy. As printed: 3,650,940. Filing ↗machine: r2 · c21 · span 463876–463885 |
| 39 | Neurogene Inc., Section 10b CEO total | DEF 14A | 2026-04-16 | 0001404644-26-000027 | CEO total compensation as printed in Neurogene Inc.'s own proxy. As printed: 3,209,553. Filing ↗machine: r2 · c21 · span 218271–218280 |
| 40 | Nkarta, Inc., Section 10b CEO total | DEF 14A | 2026-04-23 | 0001140361-26-016403 | CEO total compensation as printed in Nkarta, Inc.'s own proxy. As printed: 2,978,038. Filing ↗machine: r2 · c27 · span 344226–344235 |
| 41 | TScan Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-17 | 0001193125-26-160304 | CEO total compensation as printed in TScan Therapeutics, Inc.'s own proxy. As printed: 2,801,450. Filing ↗machine: r2 · c27 · span 220378–220387 |
| 42 | Voyager, Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001104659-26-050297 | CEO total compensation as printed in Voyager, Inc.'s own proxy. As printed: 2,508,370. Filing ↗machine: t9 · r1 · c47 · span 370852–370861 |
| 43 | Cabaletta Bio, Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-183557 | CEO total compensation as printed in Cabaletta Bio, Inc.'s own proxy. As printed: 2,401,555. Filing ↗ |
| 44 | Editas Medicine (subject), Section 10b CEO total | DEF 14A | 2026-04-28 | 0001650664-26-000037 | CEO total compensation as printed in Editas Medicine's own proxy. As printed: 2,353,655. Filing ↗machine: t42 · r2 · c12 · span 545455–545464 |
| 45 | Fate Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-177094 | CEO total compensation as printed in Fate Therapeutics, Inc.'s own proxy. As printed: 2,248,568. Filing ↗machine: r2 · c31 · span 391551–391560 |
| 46 | Tenaya Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-16 | 0001193125-26-158079 | CEO total compensation as printed in Tenaya Therapeutics, Inc.'s own proxy. As printed: 1,881,396. Filing ↗machine: r2 · c32 · span 639879–639888 |
| 47 | Caribou Biosciences, Inc., Section 10b CEO total | DEF 14A | 2026-05-01 | 0001619856-26-000028 | CEO total compensation as printed in Caribou Biosciences, Inc.'s own proxy. As printed: 1,840,965. Filing ↗machine: r2 · c39 · span 191689–191698 |
| 48 | Adicet Bio, Inc., Section 10b CEO total | DEF 14A | 2026-04-29 | 0001720580-26-000027 | CEO total compensation as printed in Adicet Bio, Inc.'s own proxy. As printed: 1,465,747. Filing ↗machine: r2 · c27 · span 482415–482424 |
| 49 | Section 10a, Lyell Immunopharma, Inc. reciprocity | DEF 14A | — | 0001140361-24-021008 | Lyell Immunopharma, Inc.'s most recent proxy was read; its disclosed peer group does not include Editas Medicine. Filing ↗ |
| 50 | Section 10a, Voyager, Inc. reciprocity | DEF 14A | — | 0001104659-26-050297 | Voyager, Inc. names Editas Medicine in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.